ArticleScience translational medicine2013
CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis.
Article in Science translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 190 citations in OpenAlex.
- Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.EBioMedicine · 2017Trial
- The lung tissue environment inbioRxiv : the preprint server for biology · 2026Article
- Ly6GeLife · 2026Article
- Development of a score derived from full blood count parameters to differentiate individuals with tuberculosis disease from those with tuberculosis infection.Clinical and experimental immunology · 2026Article
- Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies.Signal transduction and targeted therapy · 2025Review
- Article
- Global proteomics reveals pathways of mesenchymal stem cells altered by Mycobacterium tuberculosis.Scientific reports · 2024Article
- The American Association of Tissue Banks tissue donor screening for Mycobacterium tuberculosis-Recommended criteria and literature review.Transplant infectious disease : an official journal of the Transplantation Society · 2024Review
- Endosteal stem cells at the bone-blood interface: A double-edged sword for rapid bone formation: Bone marrow endosteal stem cells provide a robust source of bone-making osteoblasts both in normal and abnormal bone formation.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Article
- Detailed phenotyping reveals diverse and highly skewed neutrophil subsets in both the blood and airways during active tuberculosis infection.Frontiers in immunology · 2024Article
- Multi-omics analysis in developmental bone biology.The Japanese dental science review · 2023Review
- Article
- Detection of Mycobacterial DNA in Human Bone Marrow.Microorganisms · 2023Article
- Revisiting the role of mesenchymal stem cells in tuberculosis and other infectious diseases.Cellular & molecular immunology · 2023Review
- Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection.Tropical medicine and infectious disease · 2023Review
- Cellular dynamics of distinct skeletal cells and the development of osteosarcoma.Frontiers in endocrinology · 2023Review
- Serum amyloid A proteins reduce bone mass during mycobacterial infections.Frontiers in immunology · 2023Article
- Infection with hypervirulentFrontiers in immunology · 2023Article
- Mouse Models forPathogens (Basel, Switzerland) · 2022Review
- Antibiotic Resistance toAntibiotics (Basel, Switzerland) · 2022Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Mycobacterium tuberculosis (Mtb) can persist in hostile intracellular microenvironments evading immune cells and drug treatment. However, the protective cellular niches where Mtb persists remain unclear. We report that Mtb may maintain long-term intracellular viability in a human bone marrow (BM)-derived CD271(+)/CD45(-) mesenchymal stem cell (BM-MSC) population in vitro. We also report that Mtb resides in an equivalent population of BM-MSCs in a mouse model of dormant tuberculosis infection. Viable Mtb was detected in CD271(+)/CD45(-) BM-MSCs isolated from individuals who had successfully completed months of anti-Mtb drug treatment. These results suggest that CD271(+) BM-MSCs may provide a long-term protective intracellular niche in the host in which dormant Mtb can reside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.